72
Participants
Start Date
April 25, 2022
Primary Completion Date
January 31, 2025
Study Completion Date
January 31, 2025
co-formulated 300 mg TDF/ 200mg FTC
Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Kenya Medical Research Institute - Partners in Health Research and Development, Thika
Collaborators (1)
University of Colorado, Denver
OTHER
Kenya Medical Research Institute
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of Washington
OTHER